Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is studying icotinib following chemotherapy to see how well it works compared to chemotherapy in treating patients with resected stage IIA-IIIA NSCLC harboring EGFR mutation.
Epistemonikos ID: 9f6b3c232eda99b7cf89429e25d7cfef53025d67
First added on: May 11, 2024